Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

705.44 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up
Can Hims & Hers Health recover after the FDA removed semaglutide from its drugs shortage list? 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD. 
Via MarketBeat
Market Monitor February 25th
Market Monitor February 25th 
Via Chartmill
Why Eli Lilly Stock Popped Today
Via The Motley Fool
Market Monitor February 26th
Market Whirlwind: Nvidia (NVDA) exceeds expectations, tensions over Trump tariffs, AppLovin drops and Lucid faces leadership crisis 
Via Chartmill
Topics Government World Trade
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug. 
Via Benzinga
Topics Lawsuit
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target
Eli Lilly is investing over $50 billion in U.S. manufacturing, adding four new sites to boost domestic medicine production and create thousands of jobs. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum
Via AB Newswire
Topics Artificial Intelligence Derivatives Intellectual Property
Eli Lilly's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Unlocking the high Growth Potential of NYSE:LLY.
ELI LILLY & CO (NYSE:LLY) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NYSE:LLY). 
Via Chartmill
Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now
See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes. 
Via MarketBeat
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
Why Organovo (ONVO) Stock Is Skyrocketing
Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR program, including FXR314. 
Via Benzinga
Eli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses
Eli Lilly introduces 7.5 mg and 10 mg Zepbound vials for $499, expands self-pay options, and lowers prices on 2.5 mg and 5 mg doses for obesity treatment. 
Via Benzinga
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
From Organovo, Inc.
Via GlobeNewswire
Corcept (CORT) Q4 Earnings Report Preview: What To Look For
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Elanco (NYSE:ELAN) Surprises With Q4 Sales
Animal health company Elanco (NYSE:ELAN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.4% year on year to $1.02 billion. On the other hand, the company’s... 
Via StockStory
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Elanco (ELAN) Q4 Earnings Report Preview: What To Look For
Animal health company Elanco (NYSE:ELAN) will be announcing earnings results tomorrow before market open. Here’s what to look for. 
Via StockStory
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Via The Motley Fool
Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs. 
Via Benzinga
Topics Government
3 Magnificent Growth Stocks to Buy Right Now
Via The Motley Fool
In Flight Dining
UNH is trimming its losses, 95% of the reason I didn’t take instant triple-digit profits is because the Wing Sting is so severe. United Healthcare is FAR from being done getting smashed in the face. 
Via Talk Markets
Topics Stocks / Equities
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
The FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved. 
Via Investor's Business Daily
Eli Lilly (LLY): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Eli Lilly’s stock price fell to $872.91. Shareholders have lost 8.3% of their capital, which is disappointing considering the S&P 500 has climbed by 8.9%. This might have... 
Via StockStory
Topics Stocks
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.